Bioactivity of miltefosine against aquatic stages of Schistosoma mansoni, Schistosoma haematobium and their snail hosts, supported by scanning electron microscopy

BACKGROUND: Miltefosine, which is the first oral drug licensed for the treatment of leishmaniasis, was recently reported to be a promising lead compound for the synthesis of novel antischistosomal derivatives with potent activity in vivo against different developmental stages of Schistosoma mansoni....

Descripción completa

Detalles Bibliográficos
Autores principales: Eissa, Maha M, El Bardicy, Samia, Tadros, Menerva
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3114006/
https://www.ncbi.nlm.nih.gov/pubmed/21569375
http://dx.doi.org/10.1186/1756-3305-4-73

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3114006/
https://www.ncbi.nlm.nih.gov/pubmed/21569375
http://dx.doi.org/10.1186/1756-3305-4-73

Ejemplares similares